Clinical Trials Insight Database Guide

Table of Contents:
Scope | General Information | Database Fields | Advanced Searching
Stopwords | Limits | Tools | Changing to this Database from Another Database
Sample Documents | Copyright Information | Updated

Read about the changes to this database in the Reload News!

Scope

Clinical Trials Insight is the new standard in rapid evaluation of clinical trial evidence for pharmaceutical professionals. Every year all the clinical trials reported in over 1,700 medical and scientific journals and at major meetings are assessed. An incomparable resource for clinical intelligence, Clinical Trials Insight provides in-depth analysis of every clinical trial, identifies key study messages and evaluates the clinical and commercial impact of the study's results.
Go: Table of Contents or Back 

General Information

Producer
     

Adis International Ltd.
Private Bag 65901
Mairangi Bay
Auckland 10
New Zealand
www.adis.com
www.Adisinsight.com
Segments and Years of Coverage
  CTI (1990 - Present)
 

The limit of databases that you can select for a multifile search session is based upon database segments rather than actual databases. The Ovid multifile segment limit is set at 120 to avoid impacting your search sessions. This database includes 1 segment.

Online Update Frequency
  Weekly
Go: Table of Contents or Back 

Database Fields

The following list is sorted alphabetically by field alias. Click a field name to see the description and search information.

All Fields in this Database

  Accession Number (AN) Journal Name (JN) Study Details (SD)
  ADIS Assessment (AA) Journal Word (JX) Study End Dates (ID)
  ADIS Creation Date (DA) Language (LG) Study Identifiers (SI)
  ADIS Headline (AT) Latest Change (LC) Study Initiation Dates (ED)
  ADIS Score (AS) Maximum/Minimum Dose (MD) Study Messages (MS)
  Adverse Events Table, Notes and Text (AE) Meeting Name (MT) Study Methods (SM)
  Author (AU) Number of Females (FN) Study Name (SN)
  Author Comments (AM) Number of Males (MN) Study Perspective (SP)
  Author Institution (IN) Number of Patients (NS) Study Phase (PH)
  Brand Name (BN) Other Descriptors (OD) Study Purpose (PU)
  Clinical Relevance (CR) Page (PG) Study Status (SS)
  Comorbid Conditions (PM) Patient Age (PX) Subject Details (SU)
  Company (CO) Patient Age Keywords (PW) Subject Ethnicity (SR)
  Concomitant Medication (CM) Patient Characteristics (CH) Subject Headings (SH)
  Country (CY) Patient Inclusions/Exclusions (IE) Subject Types (ST)
  Date of Publication (DP) Pharacoeconomic Descriptors (PE) Thereapeutic Area (TA)
  Descriptors (DE) Planned Number of Patients (PL) Title (TI)
  Document Type (DT) R&D Insight Link (RD) Treatement Description (TD)
  Dose Units (DU) Reference (RF) Treatment Duration (DR)
  Drug Name (DN) Results (RB) Treatment Formulation (FO)
  Endpoints (EP) Results Highlights (RH) Treatment Group (TR)
  Frequecy of Administration (FR) Route of Administration (RO) Treatment Name (TN)
  Global Study Outcome (OT) Source (SO) Update Code (UP)
  Heading Words (HW) Study Centre (SA) Volume (VO)
  ISSN (IS) Study Control Keywords (CL) WHO and EPhMRA ATC Codes (TC)
  Issue / Part (IP) Study Design Keywords (SG) Year of Publication (YR)
 
Go: Table of Contents or Back 

Default Fields for Unqualified Searches: Searching for a term without specifying a field searches the following fields.

  ADIS Headline (AT) Drug Name (DN) Title (TI)
  Adverse Events (AE) Heading Words (HW)  
 
Go: Table of Contents or Back 

Default Fields for Display, Print, Email, and Save: The following fields are included by default for each record.

  Accession Number (AN) Document Type (DT) Study Centre (SA)
  Adis Assessment (AA) Drug Name (DN) Study Design Keywords (SG)
  ADIS Creation Date (DA) Global Study Outcome (OT) Study Details (SD)
  ADIS Headline (AT) ISSN (IS) Study Identifiers (SI)
  ADIS Score (AS) Languages (LG) Study Messages (MS)
  Adverse Events (AE) Meeting Name (MT) Study Purpose (PU)
  Author (AU) Other Descriptors (OD) Subject Details (SU)
  Author Comments (AM) Patient Age Keywords (PW) Subject Heading (SH)
  Author Institution (IN) Pharacoeconomic Descriptors (PE) Therapeutic Area (TA)
  Clinical Relevance (CR) R&D Insight Link (RD) Title (TI)
  Company (CO) Reference (RF) Treatment Group (TR)
  Country (CY) Results (RB) Update Code (UP)
  Date of Publication (DP) Results Highlights (RH) WHO and EPhMRA ATC Codes (TC)
  Descriptors (DE) Source (SO)  
 
Go: Table of Contents or Back 

All Fields for Display, Print, Email, and Save: Use the Select Fields button in the Results Manager at the bottom of the Main Search Page to choose the fields for a record.

  Accession Number (AN) Issue / Part (IP) Study Control Keywords (CL)
  Adis Assessment (AA) Journal Name (JN) Study Design Keywords (SG)
  ADIS Creation Date (DA) Languages (LG) Study Details (SD)
  ADIS Headline (AT) Latest Change (LC) Study Identifiers (SI)
  ADIS Score (AS) Maximum/Minimum Dose (MD) Study Messages (MS)
  Adverse Events (AE) Meeting Name (MT) Study Methods (SM)
  Author (AU) Number of Females (FN) Study Name (SN)
  Author Comments (AM) Number of Males (MN) Study Perspective (SP)
  Author Institution (IN) Number of Patients (NS) Study Phase (PH)
  Brand Name (BN) Other Descriptors (OD) Study Purpose (PU)
  Clinical Relevance (CR) Page (PG) Study Status (SS)
  Comorbid Conditions (PM) Patient Age (PX) Subject Details (SU)
  Company (CO) Patient Age Keywords (PW) Subject Ethnicity (SR)
  Concomitant Medication (CM) Patient Characteristics (CH) Subject Headings (SH)
  Country (CY) Patient Inclusions/Exclusions (IE) Subject Types (ST)
  Date of Publication (DP) Pharacoeconomic Descriptors (PE) Therapeutic Area (TA)
  Descriptors (DE) Planned Number of Patients (PL) Title (TI)
  Document Type (DT) R&D Insight Link (RD) Treatment Formulation (FO)
  Dose Units (DU) Reference (RF) Treatment Group (TR)
  Drug Name (DN) Results (RB) Treatment Name (TN)
  Endpoints (EP) Results Highlights (RH) Update Code (UP)
  Frequecy of Administration (FR) Route of Administration (RO) Volume (VO)
  Global Study Outcome (OT) Source (SO) WHO and EPhMRA ATC Codes (TC)
  ISSN (IS) Study Centre (SA) Year of Publication (YR)
 
Go: Table of Contents or Back 

Elements of Source (SO) Field: Ovid searches the following fields as part of the record source.

  Date of Publication (DP) Journal Name (JN) Volume (VO)
  Issue / Part (IP) Page (PG) Year of Publication (YR)
 
Go: Table of Contents or Back 

The following list is sorted alphabetically by the two-letter label, and includes the relevant alias, at least one example for all searchable fields, and a description of the field.

Label   Name / Example
AA ADIS Assessment [Word Indexed]
positive features.aa.

The ADIS Assessment (AA) field displays Positive and Negative Features about a study as well as ADIS comments.  This field is only available in Best Evidence records.

ADIS comments are also included in this field, capturing data relevant to the study obtained largely from sources other than the original article. The comment may include information on the clinical relevance of the study, the development phase of a research drug, commercial drug information, and/or strengths and weaknesses of the study design.

All A-rated assessments will contain an added-value Adis Comment. Some B-rated assessments will have Adis Comments, and C-rated assessments will only have relevant meeting information in the  Adis Comment field.
Back 
AE Adverse Events [Word Indexed]
depression.ae.

The Adverse Events (AE) field displays adverse event tables, table notes, text notes, and tolerability highlights. 

This field is only available in Best Evidence records.
Back 
AM Author Comments [Word Indexed]
galantamine.am.

The Author Comments (AM) field contains the author's concluding remarks about the study, usually a quote.

This field is only available in Best Evidence records.
Back 
AN Accession Number [Phrase Indexed]
" 801056436".an.
The Accession Number (AN) field contains a unique number assigned to each record for identification.
Back 
AS

ADIS Score [Word Indexed]
"95".as.

The Trial Design Score (AS) field displays ADIS' trial design scores. These scores fall into the following ranges:

  • 86-100   Excellent trial, highly acceptable
  • 71-85     Good to very good trial, most important elements adequate
  • 50-70     Fair trial, some important elements adequate
  • 50          Not acceptable or results require confirmation by a better designed study

Some of the criteria used to determine a design's score include clear statement of aims of the study, clear definition of the study perspective, relevance of the outcomes measured to the stated purpose of the study, relevance of the costs measured to the study perspective, and clear statement of the sources of cost and outcome data. Also included are definition and pre-trial confirmation of disease severity in accordance with accepted classification criteria, adequate size of the patient groups to show a statistically significant difference between the therapeutic response of the drugs under investigation, controls to reduce variation and bias, checks to confirm patient compliance, and the clinical relevance of the therapeutic response achieved.
Back 
AT

ADIS Headline [Word Indexed]
bacterial.at

The ADIS Headline (AT) field contains all words found in all ADIS titles for each record. 

This field is available in Best Evidence, Index Only, and Ongoing Trial records.
Back 
AU Author [Phrase Indexed]
smith j.au.
  The Author (AU) field contains the names of the author(s) of the original article from which a study or case report is taken.
Back 
BN

Brand Name[Phrase Indexed]
tamiflu.bn.

The Brand Name (BN) index contains drug name brand names.

This field displays in Treatment Group (TR) field.
Back 
CH Patient Characteristics [Word Indexed]
eczema.ch.
 

The Patient Characteristics (CH) field describes symptoms patients exhibited.

This field displays in the Study Details (SD) field.
Back 
CL Study Control Keywords [Word Indexed]
applicable.cl.
screening.cl
 

The Study Control Keywords(CL) field describes the control methodology used in the study. A study can have more than one type of control.

This field displays in the Study Details (SD) field.
Back 
CM Concomitant Medication [Word Indexed]
lithium.cm.
 

The Concomitant Medication (CM) field is a list of all drugs given concurrently, for example, those that are not the focus of the study.

This field displays in the Subject Details (SU) field.
Back 
CO Company [Word Indexed]
eli lilly.co.
  The Company (CO) field contains the names of companies associated with a study as a sponsor, co-author, or marketer/manufacturer of the drug used in a treatment.
Back 
CR Clinical Relevance [Word Indexed]
c.cr.
 

The Clinical Relevance (CR) field rates the significance of the study results on patient care.

A 3-point scale is used, and defined as:

  • A  Provides new eveidence of clinical benefit.
  • B  Provides supporting evidence to existing data.
  • C  Adds no new or important information.

This field is only available in Best Evidence records.

A limit to Clinical Relevance restricts retrieval to only records containing the chosen rating.

Back 
CY Country [Phrase Indexed]
france.cy.
 

The Country (CY) index contains the location of the country or countries in which the study population lived.

The original study report does not always clearly state this fact and in these cases ADIS does not infer the study location from the location of the institution to which the authors are affiliated.

This field displays in the Subject Details (SU) field.

A limit to country restricts retrieval to only records containing the chosen country.
Back 
DA

ADIS Creation Date [Word Indexed]
"2006".da
"2006-10".da
"2006-10-03".da

The ADIS Creation Date (DA) field contains the date when ADIS created the record, and is in YYYY, YYYY-MM, or YYYY-MM-DD format. 

The Latest Change (LC) date is indexed with the ADIS Creation Date. 

Back 
DE Descriptors [Phrase Indexed]
 

The Descriptors (DE) field contains the invalid Subject Heading (SH) terms.  This field currently contains no data.

Back 
DN Drug Name [Phrase Indexed]
antimicrobial.dn.
  The Drug Name (DN) field contains the name of the drug(s) used in studies and case reports.  It also includes ADIS' drug descriptor.
Back 
DP Date of Publication [Word Indexed]
"2004".dp
"June 1".dp
"June 1, 2004".dp.
The Date of Publication (DP) field contains the original publication date in MONTH DD, YYYY format.

This field displays in the Source (SO) field.
Back 
DR Treatment Duration [Word Indexed]
months.dr.

The Treatment Duration (DR) field describes the length of time a treatment was administered.

This field displays in the Treatment Group (TR) field.

Back 
DT Document Type [Phrase Indexed]
Best Evidence.dt.
 

The Document Type (DT) field consists of the four record types found in CTI.

  • Best Evidence (2004 onwards)
  • Index Only (1990 to 2004)
  • Ongoing Trial (2005 onwards)
  • Supporting Evidence (2005 onwards)

A limit to Document Type restricts the search to a specific document type.
Back 
DU Dose Units [Word Indexed]
day.du.

The Dose Units (DU) field describes the units in which a treatment was administered, for example, mg/day.

This field displays in the Treatment Group (TR) field.
Back 
ED Study End Dates [Word Indexed]
2006.ed.
10.ed.

The Study End Dates (ED) field contains the planned and actual end dates of a study.

This field displays in the Study Details (SD) field.
Back 
EP Endpoints [Word Indexed]
vomiting.ep.
 

The Endpoints (EP) field is used to select studies with particular endpoints as their focus. Endpoints are the important efficacy parameters measured in the study and reported as results.

This field displays in the Study Details (SD) field.
Back 
FN Number of Females [Phrase Indexed]
30.fn.
 

The Number of Females (FN) field contains the number of females initially enrolled in the study or case.

This field displays in the Subject Details (SU) field.
Back 
FO Treatment Formulation [Word Indexed]
controlled release.fo.
 

The Treatment Formulation (FO) field contains the distinct formulations in which a drug has been administered.

This field displays in the Treatment Group (TR) field.
Back 
FR Frequency of Administration [Phrase Indexed]
tid.fr.
 

The Frequency of Administration (FR) field contains the data for how often the drug is administered. The following abbreviations are used:

  od   once daily        q3mo   every 3 months
  bid   twice daily   q4w   every 4 weeks
  tid   3 times daily   d1+8   on days 1 and 8
  qid   4 times daily   d1-8   on days 1 through 8 (inclusive)
  q4h   every 4 hours   d2+5   on days 2 and 6
  5 day   5 times daily   q6w   every 6 weeks
  prn   as required   stat   at once

This field displays in the Treatment Group (TR) field.
Back 
HW Heading Words [Word Indexed]
hepatitis.hw.
 

Sometimes you may wish to retrieve every subject heading (current or discontinued) that contains a particular word; this is done by searching a single word in the Heading Word (HW) field.

This field displays in the Subject Headings (SH) field.
Back 
ID Study Initiation Dates [Word Indexed]
2006.ed.
10.ed.

The Study Initiation Dates (ID) field contains the planned and actual initiation dates of a study.

This field displays in the Study Details (SD) field.
Back 
IE Patient Inclusions / Exclusions [Word Indexed]
male.ie.

The Patient Inclusions / Exclusions (IE) field displays reasons for including or excluding patients for the study in question.

This field displays in Subject Details (SU).
Back 
IN Author Affiliation [Word Indexed]
halifax.in.
  The Author Affiliation (IN) field contains the name of the institution with which the primary author(s) are affiliated.
Back 
IP Issue / Part [Word Indexed]
"3".ip.
The Issue/Part (IP) index contains the issue or part number of cited journal. 

This field displays in the Source (SO) field.
Back 
IS ISSN [Phrase Indexed]
"1600 6135".is.
The ISSN (IS) field contains the cited journal's ISSN. 
Back 
JN Journal Name [Phrase Indexed]
"pharmacy world and science".jn.
 

The Journal Name (JN) field contains the full name of the journal in which the original study or case report appeared.

This field displays in the Source (SO) field.
Back 
JX Journal Word [Word Indexed]
medical.jx.
 

The Journal Word (JX) field contains individual words from every journal name in CTI.  This field is used to retrieve every occurrence of a journal which includes a particular word, such as "Medical".

This field displays in Source (SO).
Back 
LC Latest Change [Display Only]
  The Latest Change (LC) field indicates the most recent change to the record.
Back 
LG Language [Phrase Indexed]
english.lg.
The Language (LG) field describes the original article's language.
Back 
MD Maximum / Minimum Dose [Word Indexed]
"200000".md.

The Maximum/Minimum Dose (MD) field contains the numeric dose value. 

This field displays in the Treatment Group (TR) field.
Back 
MN Number of Males [Phrase Indexed]
13.mn.
 

The Number of Males (MN) field contains the total number of males initially enrolled in the study or case.

This field displays in the Subject Details (SU) field.
Back 
MS Study Messages [Word Indexed]
adolescents.ms.
 

The Study Messages (MS) field contains simple statements derived from the study of a basic fact about the treatment. It states the study conclusion(s) in qualitative terms. The study conclusions are based on the main results, for example the results of the stated endpoints and relevant, statistically significant others.

These are compulsory for A- and B-rated studies and optional for C's, as these studies are less likely to have a clear message.

There is a maximum of 6 study messages per assessment.  The following four message types exist: 

  • Efficacy
  • Others
  • PEC
  • Tolerability
Back 
MT Meeting Name [Word Indexed]
london.mt.
The Meeting Name (MT) field displays the conference associated with the original article.
Back 
NS Number of Patients [Phrase Indexed]
"101".ns.
 

The Number of Patients (NS) field contains the total number of subjects used in either the case or study.

This field displays in the Subject Details (SU) field.

Back 
OD Other Descriptors [Word Indexed]
coronary-interventions.od.
The Other Descriptors (OD) field contains other terms used to describe the record or study.
Back 
OT Global Study Outcome [Word Indexed]
antiallergics.ot.
The Global Study Outcome (OT) field displays information on a study's efficacy and tolerability.
Back 
PE Pharmacoeconomic Descriptors [Word Indexed]
utility.pe.
  The Pharmacoeconomic Descriptors (PE) field contains keywords expressing basic pharmacoeconomic concepts.
Back 
PG Pagination [Word Indexed]
"130".pg.
  The Pagination (PG) field contains the first page of the cited article.

This field displays in the Source (SO) field.
Back 
PH

Study Phase [Word Indexed]
ii.ph.
iv.ph.
 

Four phases of clinical trials and drug development exist in the Study Phase (PH) index. The four phases are as follows:

  Phase   Purpose
 
I
   Determine tolerability and dosage. Initial safety trials on a new medicine, usually conducted in normal male volunteers. An attempt is made to establish the dosage range tolerated by volunteers for single and multiple dosages. As well as the drug's tolerability profile and dosage range, these studies also determine how a drug is absorbed, distributed, metabolised, and excreted, and the duration of its action.
 
II
   Provide a measure of efficacy in addition to short-term tolerability. Phase II studies are conducted in patients who have the disease or condition that the drug is intended to treat. Other Phase II study objectives include determining the minimum dose that is maximally effective, or that is sufficiently effective without undue toxicity. When it is both possible and useful, Phase II studies should be controlled investigations involving a placebo or standard therapy comparator.
 
III
   Confirm efficacy, monitor adverse reactions from long-term use. In Phase III studies, a drug is tested under conditions more closely resembling those under which the drug would be used if approved for marketing. The goal is to gather additional information about efficacy and tolerability that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labelling.
 
IV
  

Provide ongoing data after regulatory (such as FDA) approval. Phase IV clinical trials are undertaken for reasons such as:

  • To satisfy a regulatory request (for example, that Phase IV trials be conducted after approval).
  • To evaluate drug efficacy and tolerability under conditions of widespread use, including in patient groups not well represented in well-controlled Phase III trials.
  • For special-purpose testing, such as cost-benefit or cost-effectiveness studies, that attempt to, for example, find specific competitive advantages of using one product over another drug or therapy.

Almost any type of clinical study may be conducted during Phase IV, including postmarketing surveillance, pharmacoepidemiology, marketing-oriented, and clinically-oriented studies. Phase IV trials are often of a larger scale than are premarketing studies, and are sometimes less rigorously controlled.

This field displays in the Study Details (SD) field.
Back 
PL Planned Number of Patients [Phrase Indexed]
"100".pl.

The Planned Number of Patients (PL) field describes how many patients were initially slated for the study.

This field displays in the Subject Details (SU) field.
Back 
PM Comorbid Conditions [Word Indexed]
diabetes.pm.
 

The Comorbid Conditions (PM) field should be used to find diseases of the patient population other than that for which they are being treated.

This field displays in the Subject Details (SU) field.
Back 
PU Study Purpose [Word Indexed]
baldacci.pu.
efficacy.pu.
tolerability.pu.
  The Study Purpose (PU) field is a statement of the study aim with or without an explanation of the study context.
Back 
PW Patient Age Keywords [Phrase Indexed]
adolescent.pw.
The Patient Age Keywords (PW) field broadly describes the patient population.
Back 
PX Patient Age [Phrase Indexed]
"25".px.

The Patient Age (PX) field can be used to search for patient minimum and maximum ages in a study. 

This field displays in the Subject Details (SD) field.
Back 
RB Results [Word Indexed]
hemorrhage.rb.
 

The Results (RB) field displays important study results in table format, including table notes and other text regarding the results.

This field only displays in Best Evidence records.
Back 
RD R&D Insight Link [Word Indexed]
"10180".rd.
The R&D Insight Link (RD) field links Clinical Trials Insight records to R & D Insight records.
Back 
RF Reference [Word Indexed]
intravascular.rf.
 

The Reference (RF) field displays articles cited during the trial/study.

This field only displays in Ongoing Trial records.

Back 
RH Results Highlights [Word Indexed]
benefit.rh.
 

The Results Highlights (RH) field contains brief text reporting the main study results and is expressed quantitatively. 

This field only displays in Best Evidence and Supporting Evidence records.
Back 
RO Route of Administration [Phrase Indexed]
po.ro.
 

The Route of Administration (RO) field contains information on which route the drug is administered into the body. The following abbreviations are most commonly used:

  IA   intra-arterial   inj   injection
  IAr   intra-articular   IV   intravenous
  ICo   intracoronary   PO   oral
  ID   intradermal   SC   subcutaneous
  IL   intralumbar   SL   sublingual
  IM   intramuscular   TD   transdermal
  inf   infusion   top   topical
  inh   inhalation        

This field displays in the Treatment Group (TR) field.
Back 
SA Study Centre [Word Indexed]
london.sa.

The Study Centre (SA) field displays the name and location of associated study centres, indicating whether or not the centre is lead or not.

This field also displays the name and contact information for lead and non-lead investigators.
Back 
SD Study Details [Display Only]
 

The Study Details (SD) field displays the following information regarding the study/trial:

This field not available in Index Only records.
Back 
SG Study Design Keywords [Word Indexed]
multicentre.sg.
 

The Study Design Keywords (SG) index contains a list of terms used to describe the design of the study.

This field displays in the Study Details (SD) field.
Back 
SH Subject Headings [Phrase Indexed]
parkinsons disease.sh.
 

The Subject Headings (SH) field displays terms found in the CTI Tree.

Use the Heading Words (HW) index to search individual words.
Back 
SI Study Identifiers [Word Indexed]
astrazeneca.si.

The Study Identifier (SI) field displays the Study Identifier Code and Study Owner. 

This field does not display in Index Only records.
Back 
SM Study Methods [Word Indexed]
regime.sm.
 

The Study Methods (SM) field contains information about the study methods that is necessary for understanding the results as presented in the assessment providing this information has not been explained anywhere else in the assessment.

This field displays in the Study Details (SD) field.
Back 
SN Study Name [Word Indexed]
accumetrics.sn.
 

The Study Name (SN) field contains the names of studies. Some studies have a formal name - often an acronym, for example, "GISSI.

This field displays in the Study Details (SD) field.
Back 
SO Source [Display Only]

The Source (SO) field displays all of the basic information needed to locate a citation, including the Journal Name (JN), Volume (VO), Issue / Part (IP) , Page (PG), Date of Publication (DP) and Year of Publication (YR).
Back 
SP Study Perspective [Word Indexed]
government.sp.

The Study Perspective (SP) field describes the social or community perspective of the study.

This field displays in the Study Details (SD) field.
Back 
SR Subject Ethnicity [Word Indexed]
whites.sr.

The Subject Ethnicity (SR) field contains the ethnic group(s) of the patient population when ethnicity is a significant focus of the study. This field is not largely populated, as a result.

This field displays in Subject Details (SU).
Back 
SS Study Status [Phrase Indexed]
in progress.ss.

The Study Status (SS) field displays the status of the study at the time of publication.

This field displays in the Study Details (SD) field.
Back 
ST Subject Types [Word Indexed]
volunteers.st
 

The Subject Types (ST) field contains the type of subject used in the study.

This field displays in the Subject Details (SU) field.

A limit to Subject Type restricts retrieval to only those records containing the subject type chosen.
Back 
SU Subject Details [Display Only]
 

The Subject Details (SU) field contains some or all of the following information about the study's subjects:
Back 
TA Therapeutic Area [Phrase Indexed]
neurological disorders.ta.
  Therapeutic Area (TA) field contains broad therapeutic categories of drugs.
Back 
TC WHO and EPhMRA ATC Codes [Word Indexed]
"100".tc.
a07e.tc.

The WHO and EPhMRA ATC Codes (TC) field details Anatomical Classification Codes from the World Health Organization and the European Pharmaceutical Market Research Association.  WHO codes are followed by the drug name and EPhMRA codes are followed by drug descriptors
Back 
TD Treatment Description [Word Indexed]
paracetamol.td.
single-dose.td.
pregnancy.td.

The Treatment Description (TD) field contains more information on how treatment was administered, monitored, and so on.

This field displays in the Treatment Group (TR) field.
Back 
TI Title [Word Indexed]
bioavailability.ti.
  The Title (TI) field contains the original article's title.
Back 
TN Treatment Name [Word Indexed]
ribavirin.tn.
 

The Treatment Name (TN) field contains the name(s) of the various treatments.

This field displays in the Treatment Group (TR) field.
Back 
TR Treatment Group [Display Only]
 

The Treatment Group (TR) field displays some or all of the following information about the treatment group:
Back 
UP Update Code [Phrase Index]
"20070509".up.
 

The Update Code (UP) field contains the date the record was last updated, in YYYYMMDD format.

A limit to the latest update restricts retrieval to documents which were most recently added to the database.
Back 
VO Volume [Phrase Indexed]
"130".vo.
 

The Volume (VO) field contains the volume for the cited article.

This field displays in the Source (SO) field.
Back 
YR Year of Publication [Phrase Indexed]
2007.yr.
 

The Year of Publication (YR) field contains the year in which the article was published.

This field displays in the Source (SO) field.
Go: Table of Contents or Back 

Advanced Searching

You can use special words and symbols to combine search terms and refine a search. For efficient searching, use the most appropriate operator from the list below to combine search terms. For more information on these and other searching techniques, including command line syntax searching, refer to the Ovid Gateway Help.

Operator Syntax Search Example Sample Results
OR x or y

heart attack or myocardial infarction

"lipid-lowering treatment to prevent heart attack trial"

 

 The OR operator retrieves records that contain any or all of the search terms. For example, the search heart attack or myocardial infarction retrieves results that contain the terms heart attack, myocardial infarction or both terms; results are all inclusive. You can use the OR operator in both unqualified searches and searches applied to a specific field.
AND x and y

transplantation and myocardial infarction

"Role of orthotopic heart transplantation in the management of patients with recurrent ventricular tachyarrhythmias following myocardial infarction"

 

 The AND operator retrieves only those records that include all of the search terms. For example, the search blood pressure and stroke retrieves results that contain the term blood pressure and the term stroke together in the same record; results are exclusive of records that do not contain both of these terms. You can use the AND operator in both unqualified searches and searches applied to a specific field.
NOT x not y

heart not attack

"Outcomes of pregnancies in female heart transplant recipients"

 

 The NOT operator retrieves records that contain the first search term and excludes the second search term. For example, the search health reform not health maintenance organizations retrieves only those records that contain the term health reform but excludes the term health maintenance organizations. In this way, you can use the NOT operator to restrict results to a specific topic.
You can use the NOT operator in both unqualified searches and searches applied to a specific field.
Adjacency (ADJ) x y

transplant recipients

"posttransplant cancers in kidney transplant recipients"

 

 The Adjacent operator (ADJ) retrieves records with search terms next to each other.You do not need to separate search terms manually by inserting ADJ between them, because when you separate terms with a space on the command line, Ovid automatically searches for the terms adjacent to one another. For example, the search blood pressure is identical to the search blood adj pressure.
Defined Adjacency (ADJn) x ADJn y

oxytocin adj7 depression

"oxytocin concentrations in treated patients with major depression"

 

 The defined adjacency operator (ADJn) retrieves records that contain search terms within a specified number (n) of words from each other in any order. To use the adjacency operator, separate your search terms with ADJ and a number from 1 to 99. For example, the search physician adj5 relationship retrieves records that contain the words physician and relationship within five words of each other in either direction. This particular search retrieves records containing such phrases as physician patient relationship, patient physician relationship, or relationship of the physician to the patient.
Frequency (FREQ) x.ti./FREQ=n

blood.ti/freq=2

 "Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm"

 

 The frequency operator (FREQ) lets you specify a threshold of occurrence of a term in the records retrieved from your search. Records containing your search term are retrieved only if the term occurs at least the specified (n) number of times. In general, records that contain many instances of your search term are more relevant than records that contain fewer instances. The frequency operator is particularly useful when searching a text field, such as Title or Full Text, for a common word or phrase.
Unlimited Truncation ($) x$

protein$

"urinary protein/creatinine ratio in tacrolimus and cyclosporine-treated renal transplant recipients"

 

 Unlimited truncation retrieves all possible suffix variations of the root word indicated. To apply unlimited truncation to a term, type the root word or phrase followed by either of the truncation characters: $ (dollar sign) or : (colon). For example, in the truncated search disease$, Ovid retrieves the word disease as well as the words diseases, diseased, and more.
Limited Truncation ($) x$n

cam$1

"Heart rate and its variability in patients with chronic heart failure"

 

 Limited truncation specifies a maximum number of characters that may follow the root word or phrase. For example, the truncated search rat$1 retrieves results with the words rat and rate; but it does not retrieve results with the word ratio.
Mandated Wildcard (#) xx#y

m#n

"HIV drug resistance among women using prophylactic antiretrovirals during pregnancy"

 

 Searching with a mandated wildcard retrieves all possible variations of a word in which the wildcard is present in the specified place. You can use it at the end of a term to limit results to only those that contain the word plus the mandated character. For example, the search dog# retrieves results that contain the word dogs, but not those that contain the word dog, effectively limiting results to only those that contain the plural form of the word. The mandated wild card character (#) is also useful for retrieving specialized plural forms of a word. For example, the search wom#n retrieves results that contain both woman and women. You can use multiple wild cards in a single query word.
Optional Wildcard (?) xx?y an?emia

"The impact of HAART on anaemia in HIV-infected children in Siem Reap, Cambodia"

 

 The optional wild card character (?) can be used within or at the end of a search term to substitute for one or no characters. This wild card is useful for retrieving documents with British and American word variants since it specifies that you want retrieval whether or not the extra character is present. For example, the optional wild card search colo?r retrieves results that contain the words color or colour. You can use multiple wild cards in a single query word.
Literal String ("") "x / y"

""E(2)/NETA""

"transdermal continuous combined E(2)/NETA"
  "n"

"3".vo

"Oral Diseases. 3 pp. 20, 1997."

 

Quotation marks can be used to retrieve records that contain literal strings, when the string includes special characters, such as a forward slash (/).

Quotation marks can also be used to retrieve records that contain numbers that may otherwise be confused for earlier searches. In the example, a search for 3.vo would limit the string from your third search in your search history to the volume field. By including the number in quotation marks, the search will retrieve documents with a 3 in the volume number.
Go: Table of Contents or Back 

Stopwords

At customer request, StopWords have been eliminated from this database. You can now search for words or phrases like is there hope.tw.  Previously such searches would have returned an error because they included stopwords.
Go: Table of Contents or Back 

Limits

The following limits are available from the Limit a Search Page. Access this page by clicking the More Limits icon on the Main Search Page.

Limit

 Syntax
Age Group Sentence Syntax:

limit 1 to infant

 

A limit to Age Group will restrict retrieval to only those records containing the age group chosen.

The groups are defined as follows:

  fetus   7-8 weeks gestation to birth
  neonate   0-4 weeks
  infant   1-23 months
  child   2-12 years
  adolescent   13-18 years
  adult   19-64 years
  elderly   >=65 years

Clinical Relevance

Sentence Syntax:

limit 1 to A

 

A limit to Clinical Relevance restricts retrieval to records containing the chosen rating.

The ratings are defined as follows:

  • A  Provides new eveidence of clinical benefit.
  • B  Provides supporting evidence to existing data.
  • C  Adds no new or important information.
Country Sentence Syntax:

limit 1 to france

 

A limit to Country restricts retrieval to only records containing the chosen country.
Document Type Sentence Syntax:

limit 1 to Index Only

 

A limit to Document Type restricts retrieval to one of the four types of documents:

  • Best Evidence
  • Index Only
  • Ongoing Trial
  • Supporting Evidence
English Language Sentence Syntax:

limit 1 to english language

 

A limit to English Language restricts retrieval to documents written in English.
Females Only Sentence Syntax:

limit 1 to females
 

A limit to females restricts retrieval to studies and cases containing only females.
Full Text Sentence Syntax:

limit 1 to full text

 

 
Latest Update Sentence Syntax:

limit 1 to latest update

 

A limit to Latest Update restricts retrieval to documents which were most recently added to the database.

Males Only

Sentence Syntax:

limit 1 to males only

 

A limit to males restricts retrieval to studies and cases containing only males.
Publication Year Sentence Syntax:

limit 1 to yr="2005 "
limit 1 to yr="2005 - 2006"

 

A limit to publication year restricts retrieval to records containing the publication year(s) chosen as found in the Reference (RF) field.
Study Phase Sentence Syntax: limit 1 to phase iii
 

A limit to study phase restricts retrieval to the phase chosen.
Subject Ethnicity Sentence Syntax: limit 1 to whites
 

This limit restricts retrieval to records containing the Subject Ethnicity chosen. Subject Ethnicity is noted when ethnicity is a significant focus of the study.
Subject Types Sentence Syntax: limit 1 to volunteers
 

A limit to Subject Types restricts retrieval to only those records containing the subject type chosen.
Therapeutic Area Sentence Syntax: limit 1 to antifungals
 

This limit restricts retrieval to records containing the Therapeutic Area chosen. Therapeutic Areas are broad therapeutic categories of drugs.
Go: Table of Contents or Back 

Tools

The following Search Tools are available for this database. For specific information on using these tools, refer to the Ovid Gateway Help.
  • Tree
  • Permuted Index
  • Scope Note
  • Explode
Go: Table of Contents or Back 

Changing to this Database from Another Database

To change a search session to a segment of this database from another database or another segment, use the following syntax:

Command Syntax:  

..c/cti
Sentence Syntax:  

use cti

Go: Table of Contents or Back 

Sample Documents

<Sample 1>

Copyright Adis International 2007*

Accession Number
   700013547  
Document Type
   Ongoing Trial
ADIS Headline
   Title: Cyanocobalamin
   Title Qualifier: therapeutic use
   First Subtitle: Seasonal allergic rhinitis
   Second Subtitle: In patients with moderate-to-moderately severe
   disease  
Study Identifiers  
   700013547 (Clinical Trials Insight)
   700014152 (Clinical Trials Insight)  
Study Details  
   Study Status: In progress
   Planned Start: 2006-07-01
   Planned Finish: 2006-11-01
   Phase: III
   Endpoints: Total-nasal-symptom-score
 
Patient Age Keywords  
   not stated  
Therapeutic Area
   Obstructive Airways Disease  
WHO and EPhMRA ATC Codes
   B03BA01 (WHOATC) - Cyanocobalamin
   B03X (EPHMRA) - OTHER ANTI-ANAEMIC PRODUCTS, INCLUDING FOLIC ACID,
   FOLINIC ACID
Subject Headings
   Seasonal-allergic-rhinitis
Drug Name
   Cyanocobalamin : therapeutic use
References
   Cobalis Provides Update on Clinical Program For PreHistin(R);
   Announces Study Design Involving Twin Phase III Clinical Trials.. 
   Media Release: 14 Jun 2006. Available from: URL:
   http://www.cobalis.com
   Cobalis Initiates Twin Phase III Clinical Trials for PreHistin(TM)..
   Media Release: 25 Jul 2006. Available from: URL: 
   http://www.cobalis.com
   Cobalis Completes Enrollment in Twin Phase III Clinical Trials for 
   PreHistin(R).. Media Release: 6 Sep 2006. Available from: URL:
   http://www.cobalis.com
ADIS Creation Date
   2006-06-26
Update Code
   20070509
 
<Sample 2>

*Copyright Adis International 2007*

Accession Number
   800699474
Author
   DeStefani A; Usni A; Lerda W.
Title
   Operable oral cavity and oropharynx squamous cell carcinoma treated
   with interleukin-2: randomized trial.  
Source
   Oral Diseases. 3 pp. 20, 1997.  
Meeting Name
   International Congress on Oral Cancer (5th : September 1997 : 
   London, England)  
Document Type 
   Index Only 
Issn
   1354-523X  
Therapeutic Area
   Oncology
WHO and EPhMRA ATC Codes  
   J05 (WHOATC) - ANTIVIRALS FOR SYSTEMIC USE
   L03AC01 (WHOATC) - Aldesleukin
   J05C (EPHMRA) - HIV ANTIVIRALS
   L03A (EPHMRA) - IMMUNOSTIMULATING AGENTS EXCLUDING INTERFERONS
Language
   English
Subject Headings  
   Head-and-neck-cancer
   Squamous-cell-cancer  
Other Descriptors  
   Biotechnology, Randomised-controlled-trials  
Drug Name  
   Aldesleukin : therapeutic use  
ADIS Creation Date  
   1998-09-10  
Update Code
   20070509
Go: Table of Contents or Back 

Producer Copyright Information

Copyright (c) * Adis International 2007
Database Guide last updated September 8, 2007.
Go: Table of Contents or Back